Innovative Paradigms for ART: Implementation Insights From an Expert Panel

Learn about new paradigms for ART, including two-drug ART regimens and injectable long-acting ART, as a panel of faculty debates the most pressing questions in the field, exploring what the data say, what clinicians think, and what patients want.
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Program Director
Andrea Mantsios, PhD
Anthony M. Mills, MD
Omar Sued, MD, PhD
Babafemi Taiwo, MBBS

Downloadable Slideset

Download slide highlights from our live symposium.

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Andrea Mantsios, PhD Anthony M. Mills, MD Omar Sued, MD, PhD Babafemi Taiwo, MBBS
Released: July 19, 2019

FAQ Module

Learn from expert faculty as they respond to the most pressing questions on evolving paradigms in ART, including two-drug regimens and long-acting injectable therapy.

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Andrea Mantsios, PhD Anthony M. Mills, MD Omar Sued, MD, PhD Babafemi Taiwo, MBBS
Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: September 24, 2019 Expiration: September 23, 2020

Download slide highlights of expert faculty responses to the most pressing clinician questions on novel ART.

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Andrea Mantsios, PhD Anthony M. Mills, MD Omar Sued, MD, PhD Babafemi Taiwo, MBBS
Released: September 24, 2019

Video Module

Watch this CME-certified on-demand Webcast of a CCO symposium at IAS 2019 to gain expert perspectives on evolving paradigms in ART, including two-drug regimens and long-acting injectable therapy. Learn from an international faculty panel as they engage in detailed discussions about novel ART approaches.

ClinicalThought

Current HIV guidelines limit their recommendations for dual ART, but I expect positive data will soon change this.

Omar Sued, MD, PhD Released: September 20, 2019

The question of which patients are candidates for long-acting ART might be a question of which patients want it.

Andrea Mantsios, PhD Released: September 27, 2019

Less frequent dosing may be a welcome theme among HIV drugs under investigation.

Babafemi Taiwo, MBBS Released: October 10, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?